Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges.
Combination therapy
Enhancer of zeste homolog 2
Immune checkpoint inhibitors
Immunotherapy
Small cell lung cancer
Tumor microenvironment
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
05 08 2019
05 08 2019
Historique:
received:
30
01
2019
accepted:
24
07
2019
entrez:
7
8
2019
pubmed:
7
8
2019
medline:
29
8
2020
Statut:
epublish
Résumé
Management of small cell lung cancer (SCLC) has not changed over the last decades. In more recent years, alterations of DNA repair machinery and other molecular pathways have been identified in SCLC and preclinical data suggest that dysregulation of these pathways might offer new therapeutic opportunities.While immune checkpoint inhibitors (ICIs) have had a major impact on the clinical outcome of several solid tumors, including non-small cell lung cancer, the potential role of ICIs is currently under investigation in SCLC and some promising data are available. However, several clinical and biological hurdles have to be overcome and predictive markers are still eagerly needed. Knowledge of molecular pathways specifically involved in SCLC growth and treatment resistance is essential for a more rational planning of new combinations including ICIs.The present manuscript summarizes the current clinical evidence on immunotherapy in SCLC, describes the molecular bases underlying treatment resistance and discusses the potentialities and the rationale of different therapeutic combinations.
Identifiants
pubmed: 31383005
doi: 10.1186/s40425-019-0690-1
pii: 10.1186/s40425-019-0690-1
pmc: PMC6683488
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
205Références
Lancet. 1999 Jan 9;353(9147):117-8
pubmed: 10023900
J Clin Oncol. 1999 Feb;17(2):658-67
pubmed: 10080612
J Clin Oncol. 2002 Jul 15;20(14):3054-60
pubmed: 12118018
J Clin Oncol. 2002 Dec 15;20(24):4665-72
pubmed: 12488411
Lung Cancer. 2003 Mar;39(3):303-13
pubmed: 12609569
Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4275-80
pubmed: 20160101
Anticancer Res. 2010 Sep;30(9):3643-8
pubmed: 20944148
Int J Cancer. 2012 Sep 15;131(6):E928-37
pubmed: 22532287
Chest. 2013 Jan;143(1):146-151
pubmed: 22847040
Ann Oncol. 2013 Jan;24(1):75-83
pubmed: 22858559
Cancer Discov. 2012 Sep;2(9):798-811
pubmed: 22961666
Immunity. 2013 Apr 18;38(4):729-41
pubmed: 23562161
J Clin Invest. 2014 Feb;124(2):687-95
pubmed: 24382348
J Thorac Oncol. 2014 Apr;9(4):497-505
pubmed: 24736072
Oncol Rep. 2014 Jul;32(1):243-9
pubmed: 24841948
J Cancer Res Clin Oncol. 2014 Dec;140(12):2021-5
pubmed: 25012251
J Thorac Oncol. 2015 Mar;10(3):426-30
pubmed: 25384063
J Clin Oncol. 2014 Dec 10;32(35):4012-9
pubmed: 25385727
Cancer Cell. 2015 Apr 13;27(4):450-61
pubmed: 25858804
Nature. 2015 Aug 6;524(7563):47-53
pubmed: 26168399
Sci Rep. 2015 Oct 14;5:15179
pubmed: 26462617
PLoS One. 2015 Nov 25;10(11):e0143558
pubmed: 26606748
J Thorac Oncol. 2016 Mar;11(3):300-11
pubmed: 26723244
Eur J Immunol. 2016 Mar;46(3):513-22
pubmed: 26773716
J Thorac Oncol. 2016 Jun;11(6):789-800
pubmed: 26845192
Lancet Oncol. 2016 Jul;17(7):883-895
pubmed: 27269741
J Thorac Oncol. 2016 Sep;11(9):1511-21
pubmed: 27296105
J Clin Oncol. 2016 Nov 1;34(31):3740-3748
pubmed: 27458307
Oncotarget. 2016 Nov 22;7(47):76534-76550
pubmed: 27708213
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Science. 2016 Nov 4;354(6312):618-622
pubmed: 27811275
Clin Cancer Res. 2017 Jul 1;23(13):3316-3324
pubmed: 28119362
Cancer Cell. 2017 Feb 13;31(2):286-299
pubmed: 28196596
Neurology. 2017 Apr 4;88(14):1334-1339
pubmed: 28251917
Cancer Res. 2017 Jul 15;77(14):3870-3884
pubmed: 28490518
Nat Rev Clin Oncol. 2017 Sep;14(9):549-561
pubmed: 28534531
Pharmacol Ther. 2017 Dec;180:16-23
pubmed: 28579387
Cell Rep. 2017 Jul 25;20(4):854-867
pubmed: 28746871
J Clin Oncol. 2017 Dec 1;35(34):3823-3829
pubmed: 28813164
Nature. 2017 Aug 24;548(7668):471-475
pubmed: 28813415
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
Oncogene. 2018 Jan 25;37(4):502-511
pubmed: 28967900
Crit Rev Oncol Hematol. 2017 Nov;119:30-39
pubmed: 29065983
Transfus Med Hemother. 2017 Sep;44(5):320-326
pubmed: 29070977
Jpn J Clin Oncol. 2018 Jan 1;48(1):26-30
pubmed: 29077861
Nat Commun. 2017 Nov 24;8(1):1751
pubmed: 29170499
Eur J Cancer. 2018 Mar;91:21-29
pubmed: 29331748
J Thorac Oncol. 2018 May;13(5):636-648
pubmed: 29378266
Br J Cancer. 2018 Apr;118(7):933-935
pubmed: 29531322
Transl Lung Cancer Res. 2018 Feb;7(1):50-68
pubmed: 29535912
Clin Cancer Res. 2018 Apr 15;24(8):1816-1823
pubmed: 29549159
Mol Carcinog. 2018 Jul;57(7):903-910
pubmed: 29573475
Ther Adv Med Oncol. 2018 Apr 02;10:1758835918763744
pubmed: 29636826
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Cancer Cell. 2018 May 14;33(5):853-861.e4
pubmed: 29731394
J Clin Oncol. 2018 Jul 1;36(19):1905-1912
pubmed: 29746230
Cancer Discov. 2018 Jul;8(7):822-835
pubmed: 29773717
J Thorac Oncol. 2018 Sep;13(9):1393-1399
pubmed: 29775808
J Clin Oncol. 2018 Aug 10;36(23):2386-2394
pubmed: 29906251
Eur J Cancer. 2018 Sep;101:191-200
pubmed: 30077124
Nat Med. 2018 Sep;24(9):1441-1448
pubmed: 30082870
J Clin Oncol. 2018 Oct 1;36(28):2872-2878
pubmed: 30125216
Oncol Lett. 2018 Oct;16(4):4105-4113
pubmed: 30214551
Biochem Pharmacol. 2018 Oct;156:479-490
pubmed: 30222967
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
Clin Cancer Res. 2019 Jan 15;25(2):496-505
pubmed: 30327308
J Clin Oncol. 2019 Jan 20;37(3):222-229
pubmed: 30523756
J Thorac Oncol. 2019 Jan;14(1):e5-e7
pubmed: 30579553
J Thorac Oncol. 2019 May;14(5):903-913
pubmed: 30664989
Int J Mol Sci. 2019 Apr 16;20(8):null
pubmed: 30995715
Int J Radiat Oncol Biol Phys. 1995 Aug 30;33(1):77-82
pubmed: 7642434